An investigation of applications for new drugs has revealed large-scale data fraud.
By
Signe Dean

3 Oct 2016 - 3:51 PM  UPDATED 3 Oct 2016 - 3:53 PM

Clinical trial data is being manipulated on a large scale, according to an extensive review of trials for new pharmaceuticals in China.

As reported in the Economic Information Daily newspaper earlier in September, the Chinese State Food and Drug Administration performed a one-year review of 1,622 clinical trials of pharmaceutical drugs awaiting approval for entering the market. 

They concluded that more than 80 per cent of the clinical trial data was “fabricated,” incomplete, untraceable or failed to meet requirements for analysis. According to the report, some pharmaceutical companies have allegedly tampered with data that did not match the expectations for the drug, or have been hiding or deleting records of unwanted side effects.  

“More than 80 per cent of applications for mass production of new drugs have been cancelled in the light of the findings, with officials warning that further evidence [of] malpractice could still emerge in the scandal,” reports Radio Free Asia (RFA).

These applications were all for Western-style drugs, rather than traditional medicine. Experts interviewed by RFA noted that the issue in Chinese pharmaceuticals manufacturing lies not with a lack of rigorous standards for clinical trials, but rather with their implementation.

"I don't think that the 80 per cent figure is overstated," healthcare professional Luo Liang told RFA. "If you compare Western pharmaceuticals manufactured overseas with those manufactured in China, there is a huge difference in the ingredients; the quality of the China-made drugs is appalling."

Some of the ‘new’ drugs in the applications for mass manufacturing were found to be combinations of drugs already on the market, with clinical trial outcomes written before the data was gathered.

The clinical trials scandal in China, while specific to the national market and regulatory framework, is also a reminder of problems inherent in the system of clinical trials across the pharmaceutical industry at large.

For example, to highlight the fact that companies and researchers routinely withhold the results of clinical trials, UK evidence-based medicine activist Dr Ben Goldacre started an AllTrials campaign in 2013, demanding that planned trials are registered before starting them to ensure transparency and accountability of results.

“There’s a real problem in the way that clinical trials report their results. You can measure the outcome of your trial in hundreds of different ways,” Goldacre told Cosmos magazine earlier this year.

“That’s why traditionally we ask people at the beginning of a clinical trial to specify exactly what they are going to measure as the success criteria, and exactly how they are going to measure it.” 

Read these too
Misuse of popular arthritis drug linked to eight deaths since 2000
Apparently it's too easy to overdose, and potentially die, from this popular rheumatoid arthritis drug.
Testing drugs on animals could soon be a thing of the past
Rapid progress in a number of areas could soon make animal drug testing obsolete, writes pharmaceuticals researcher Laura Waters.
Not just #creatorgate: Most scandalous retractions in science
Last week's "creationist biomechanics" paper reminds us that far worse things have happened in science - here are some of them.
Australian cancer drug US deal worth up to $730m
An Australian-developed cancer drug will go to clinical trials after being licenced to US pharmaceutical giant Merck in deal worth up to $730 million.